Mirum Pharmaceuticals (MIRM) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings or view top-rated stocks.

4 brokers have issued 12-month target prices for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $81.00. On average, they anticipate the company's share price to reach $49.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price.
View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts.

Mirum Pharmaceuticals' stock was trading at $19.50 at the start of the year. Since then, MIRM stock has increased by 33.9% and is now trading at $26.11.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MIRM earnings forecast.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.01. The company earned $27.91 million during the quarter, compared to analysts' expectations of $24.99 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 91.76% and a negative net margin of 134.90%.

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Products ETF (BBP), Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Mirum Pharmaceuticals issued an update on its first quarter 2023 earnings guidance on Wednesday, April, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $31.50 million-$31.50 million, compared to the consensus revenue estimate of $26.03 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

(MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Mirum Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.50%), State Street Corp (3.08%), AXA S.A. (2.34%), Pictet Asset Management SA (2.11%), Perceptive Advisors LLC (1.58%) and Prosight Management LP (1.49%). Insiders that own company stock include Christopher Peetz, Ian Clements, James E Flynn, John A Maurer, Michael G Grey, Niall O'donnell and Pamela Vig.
View institutional ownership trends.

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MIRM stock can currently be purchased for approximately $26.11.

Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $992.96 million and generates $77.06 million in revenue each year. The company earns $-135,660,000.00 in net income (profit) each year or ($3.65) on an earnings per share basis.

The company employs 137 workers across the globe.

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com.